Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

Author(s):
Luscher, T.F.; Taddei, S.; Kaski, J.C.; Jukema, J.W. (0000-0002-3246-8359); Kallend, D.; Munzel, T.; Kastelein, J.J.P.; Deanfield, J.E.; Dal-VESSEL Investigators
Published
2012
Publication type
Article / Letter to editor
High-densityLipoproteinCholesterol (HDL-C)TorcetrapibDalcetrapib
Date issued
2012-04-30
Language
English
Is part of
European Heart Journal (2012), Vol. 33, no. 7, p. 857-+
hdl
1887/98281
doi
10.1093/eurheartj/ehs019